Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study

Maria Bibi Lyng, Anne-Vibeke Lænkholm, Qihua Tan, Werner Vach, Karina Hedelund Gravgaard, Ann Knoop, Henrik Jørn Ditzel

12 Citationer (Scopus)

Abstract

Tamoxifen significantly improves outcome for estrogen receptor-positive (ER+) breast cancer, but the 15-year recurrence rate remains 30%. The aim of this study was to identify gene profiles that accurately predicted the outcome of ER+ breast cancer patients who received adjuvant Tamoxifen mono-therapy.
OriginalsprogEngelsk
TidsskriftP L o S One
Vol/bind8
Udgave nummer1
Sider (fra-til)e54078
ISSN1932-6203
DOI
StatusUdgivet - 2013

Fingeraftryk

Dyk ned i forskningsemnerne om 'Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study'. Sammen danner de et unikt fingeraftryk.

Citationsformater